NASDAQ · CGEN
Healthcare · Biotechnology
$2.47
Up+$0.01 (+0.41%)
Updated Sep 12, 2026, 12:04 PM
SID Score
5.0/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
CGEN closed at $2.47 after 20 trading sessions, up 2.49% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 11, 2026 | $2.47 | $2.4961 | $2.43 | $2.47 | 162.16K |
| Sep 10, 2026 | $2.48 | $2.51 | $2.44 | $2.46 | 206.98K |
| Sep 9, 2026 | $2.55 | $2.55 | $2.46 | $2.48 | 293.78K |
| Sep 8, 2026 | $2.55 | $2.625 | $2.55 | $2.56 | 192.9K |
| Sep 4, 2026 | $2.54 | $2.61 | $2.54 | $2.59 | 199.7K |
| Sep 3, 2026 | $2.64 | $2.66 | $2.535 | $2.555 | 163.62K |
| Sep 2, 2026 | $2.56 | $2.63 | $2.555 | $2.63 | 127.92K |
| Sep 1, 2026 | $2.56 | $2.60 | $2.53 | $2.59 | 168.93K |
| Aug 31, 2026 | $2.63 | $2.63 | $2.52 | $2.56 | 175.12K |
| Aug 28, 2026 | $2.72 | $2.72 | $2.5801 | $2.60 | 228.79K |
| Aug 27, 2026 | $2.86 | $2.86 | $2.72 | $2.76 | 301.27K |
| Aug 26, 2026 | $2.83 | $2.935 | $2.80 | $2.84 | 667.03K |
| Aug 25, 2026 | $2.60 | $2.91 | $2.59 | $2.87 | 799.79K |
| Aug 24, 2026 | $2.58 | $2.605 | $2.49 | $2.59 | 218.36K |
| Aug 21, 2026 | $2.64 | $2.77 | $2.61 | $2.615 | 447.16K |
| Aug 20, 2026 | $2.54 | $2.68 | $2.47 | $2.65 | 993.92K |
| Aug 19, 2026 | $2.36 | $2.48 | $2.36 | $2.44 | 212.89K |
| Aug 18, 2026 | $2.33 | $2.39 | $2.30 | $2.38 | 98.19K |
| Aug 17, 2026 | $2.38 | $2.40 | $2.33 | $2.35 | 201.49K |
| Aug 14, 2026 | $2.40 | $2.43 | $2.355 | $2.41 | 191.23K |
The latest Smart Investors Daily articles mentioning CGEN.
CGEN research
Company profile and research snapshot.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| May 21, 2026 | Leerink Partners | Outperform | — |
| Apr 7, 2026 | Lake Street | Buy | — |
| Jan 7, 2026 | HC Wainwright & Co. | Buy | — |
| May 21, 2024 | Truist Securities | Buy | — |
| Mar 8, 2024 | Truist Securities | Buy | — |
No generated briefing is available yet.
Yahoo · Sep 8, 2026
Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery powered by AI, today announced that management will participate in a fireside chat and hold one-on-one meetings at the H.C. Wainwright 28th Annual Global Investment Conference, being held from September 14-16 in New York City.
Yahoo · Aug 31, 2026
Compugen (CGEN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
SeekingAlpha · Aug 6, 2026
SeekingAlpha · Aug 3, 2026
Compugen Ltd. (CGEN) Q2 2026 Earnings Call August 3, 2026 8:30 AM EDTCompany ParticipantsLindsey TrickettEran Ophir - CEO, President & DirectorDavid...
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning CGEN.
